Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2Recruiting 2Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1870Neoplasms 1254Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 801Carcinoma, Hepatocellular 784Lung Neoplasms 768Prostatic Neoplasms 697Pancreatic Neoplasms 578Rectal Neoplasms 447Ovarian Neoplasms 406Colonic Neoplasms 405Uterine Cervical Neoplasms 400Neoplasm Metastasis 400Recurrence 380Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 329Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 263Urinary Bladder Neoplasms 254Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 215Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 204

Interventions

atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Safety Issues × Clear all
NCT05580172 2022-10-17

Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer

ReHeva Biosciences,Inc.

Phase 1 Unknown
6 enrolled

Safety Issues

NCT03620435 2018-08-13

Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer

McGill University Health Centre/Research Institute of the McGill University Health Centre

Phase 2 Unknown
25 enrolled

Safety Issues

Data powered by HemOnc (CC BY 4.0) Colophon âš¡